> top > docs > PMC:1283364 > spans > 2923-3208 > annotations

PMC:1283364 / 2923-3208 JSONTXT

Annnotations TAB JSON ListView MergeView

craft-sa-dev

Id Subject Object Predicate Lexical cue
T818 2-8 VB denotes arrest
T836 9-11 CC denotes or
T837 12-19 VB denotes reverse
T838 20-23 DT denotes the
T839 24-35 NN denotes progression
T840 36-40 IN denotes from
T841 41-48 NN denotes peptide
T842 49-51 IN denotes to
T843 52-60 NN denotes dementia
T844 60-61 . denotes .
T845 61-273 sentence denotes Early evidence from clinical trials of antibody-mediated clearance, one of the first Aβ-lowering approaches tested in humans, suggested that treatments designed to reduce amyloid burden may indeed be beneficial.
T846 62-67 JJ denotes Early
T847 68-76 NN denotes evidence
T848 188-197 VBD denotes suggested
T849 77-81 IN denotes from
T850 82-90 JJ denotes clinical
T851 91-97 NNS denotes trials
T852 98-100 IN denotes of
T853 101-109 NN denotes antibody
T854 110-118 VBN denotes mediated
T855 109-110 HYPH denotes -
T856 119-128 NN denotes clearance
T857 128-130 , denotes ,
T858 130-133 CD denotes one
T859 134-136 IN denotes of
T860 137-140 DT denotes the
T861 159-169 NNS denotes approaches
T862 141-146 JJ denotes first
T863 147-149 NN denotes Aβ
T864 150-158 VBG denotes lowering
T865 149-150 HYPH denotes -
T866 170-176 VBN denotes tested
T867 177-179 IN denotes in
T868 180-186 NNS denotes humans
T869 186-188 , denotes ,
T870 198-202 IN denotes that
T871 259-261 VB denotes be
T872 203-213 NNS denotes treatments
T873 214-222 VBN denotes designed
T874 223-225 TO denotes to
T875 226-232 VB denotes reduce
T876 233-240 NN denotes amyloid
T877 241-247 NN denotes burden
T878 248-251 MD denotes may
T879 252-258 RB denotes indeed
T880 262-272 JJ denotes beneficial
T881 272-273 . denotes .
T883 274-282 IN denotes Although
R448 T836 T818 cc or,arrest
R449 T837 T818 conj reverse,arrest
R450 T838 T839 det the,progression
R451 T839 T837 dobj progression,reverse
R452 T840 T839 prep from,progression
R453 T841 T840 pobj peptide,from
R454 T842 T840 prep to,from
R455 T843 T842 pobj dementia,to
R456 T844 T818 punct .,arrest
R457 T846 T847 amod Early,evidence
R458 T847 T848 nsubj evidence,suggested
R459 T849 T847 prep from,evidence
R460 T850 T851 amod clinical,trials
R461 T851 T849 pobj trials,from
R462 T852 T851 prep of,trials
R463 T853 T854 npadvmod antibody,mediated
R464 T854 T856 amod mediated,clearance
R465 T855 T854 punct -,mediated
R466 T856 T852 pobj clearance,of
R467 T857 T856 punct ", ",clearance
R468 T858 T856 appos one,clearance
R469 T859 T858 prep of,one
R470 T860 T861 det the,approaches
R472 T862 T861 amod first,approaches
R473 T863 T864 npadvmod Aβ,lowering
R474 T864 T861 amod lowering,approaches
R475 T865 T864 punct -,lowering
R476 T866 T861 acl tested,approaches
R477 T867 T866 prep in,tested
R478 T868 T867 pobj humans,in
R479 T869 T848 punct ", ",suggested
R480 T870 T871 mark that,be
R481 T871 T848 ccomp be,suggested
R482 T872 T871 nsubj treatments,be
R483 T873 T872 acl designed,treatments
R484 T874 T875 aux to,reduce
R485 T875 T873 advcl reduce,designed
R486 T876 T877 compound amyloid,burden
R487 T877 T875 dobj burden,reduce
R488 T878 T871 aux may,be
R489 T879 T871 advmod indeed,be
R490 T880 T871 acomp beneficial,be
R491 T881 T848 punct .,suggested
R471 T861 T859 pobj approaches,of

craft-ca-core-ex-dev

Below, discontinuous spans are shown in the chain model. You can change it to the bag model.

Id Subject Object Predicate Lexical cue
T633 41-48 CHEBI_SO_EXT:peptide_or_peptide_region denotes peptide
T634 101-109 GO:0042571 denotes antibody
T635 147-149 CHEBI_PR_EXT:amyloid_beta denotes Aβ
T636 180-186 NCBITaxon:9606 denotes humans
T637 233-240 CHEBI:60425 denotes amyloid

craft-ca-core-dev

Below, discontinuous spans are shown in the chain model. You can change it to the bag model.

Id Subject Object Predicate Lexical cue
T559 101-109 GO:0042571 denotes antibody
T560 180-186 NCBITaxon:9606 denotes humans
T561 233-240 CHEBI:60425 denotes amyloid